Literature DB >> 25222072

Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.

Jared D Sturgeon1, Christopher H Crane, Sunil Krishnan, Bruce D Minsky, John M Skibber, Miguel A Rodriguez-Bigas, George J Chang, Y Nancy You, Cathy Eng, Prajnan Das.   

Abstract

OBJECTIVES: Squamous cell carcinoma (SCC) of the rectum is a rare disease with <80 cases reported in the English literature. We reviewed outcomes in patients with SCC of the rectum treated with definitive chemoradiation at a single institution.
MATERIALS AND METHODS: We identified 14 patients treated definitively with chemoradiation for SCC of the rectum. All patients were female and the median age was 56 years at presentation. Patients were treated with external beam radiation therapy with a median dose of 54 Gy (range, 38 to 58.8 Gy). All patients received concurrent chemotherapy, with 5-flourouracil and cisplatin in 10 patients and capecitabine and cisplatin in 4 patients.
RESULTS: The median follow-up was 4.5 years (range, 1.8 to 16.3 y). Only 3 of the 14 patients had relapse or persistent disease, and 2 of these underwent successful salvage surgery. The remaining 11 patients had no evidence for local or distant relapse after chemoradiation. Only 1 patient died of SCC of the rectum, 1 died of a second primary, and 12 are alive with no evidence of disease. The 5-year actuarial overall survival, disease-free survival, and disease-specific survival rates were 81%, 72%, and 88% respectively.
CONCLUSIONS: Chemoradiation is an ideal strategy for definitive therapy of SCC of the rectum with excellent disease-free survival and overall survival. In patients with local failure, salvage surgery can provide excellent outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 25222072     DOI: 10.1097/COC.0000000000000126

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

1.  Comparison of outcomes between rectal squamous cell carcinoma and adenocarcinoma.

Authors:  Max S Chiu; Vivek Verma; Nathan R Bennion; Abhijeet R Bhirud; Jinluan Li; Mary E Charlton; Chandrakanth Are; Chi Lin
Journal:  Cancer Med       Date:  2016-10-26       Impact factor: 4.452

2.  A systematic and comprehensive analysis of colorectal squamous cell carcinoma: Implication for diagnosis and treatment.

Authors:  Yang Yang; Jiarui Yu; Jitao Hu; Chaoxi Zhou; Jian Niu; Hongqing Ma; Jiaxu Han; Shaoqing Fan; Youqiang Liu; Yalei Zhao; Lianmei Zhao; Guiying Wang
Journal:  Cancer Med       Date:  2022-02-23       Impact factor: 4.711

3.  A primary squamous cell carcinoma of the sigmoid colon in a young patient: A case report and literature review.

Authors:  Mohanad Faisal; Ahmed Abdalhadi; M Zaki Karzoun; Mohamed Aboagla Suliman Mohamed; Mouhammad Zuhair Sharaf Elden; Alaaeldin Shablak
Journal:  Clin Case Rep       Date:  2022-08-16

4.  Evaluating treatment protocols for rectal squamous cell carcinomas: the Duke experience and literature.

Authors:  Erin J Song; Corbin D Jacobs; Manisha Palta; Christopher G Willett; Yuan Wu; Brian G Czito
Journal:  J Gastrointest Oncol       Date:  2020-04

5.  Chemoradiation therapy with S-1 for primary squamous cell carcinoma of the rectum: report of three cases.

Authors:  Kimihiko Funahashi; Tetsuo Nemoto; Junichi Koike; Akiharu Kurihara; Hiroyuki Shiokawa; Mistunori Ushigome; Tomoaki Kaneko; Kenichiro Arai; Yasuo Nagashima; Takamaru Koda; Takayuki Suzuki; Satoru Kagami; Yu Suitsu; Hironori Kaneko; Toshikazu Shibuya
Journal:  Surg Case Rep       Date:  2015-02-10

6.  Case Report: Management of rectal squamous cell carcinoma - a treatment dilemma.

Authors:  Nathaniel A Parker; Yasmine Hussein Agha; Charles Scott Buess; Daniel Lalich; Jeremy M Deutsch
Journal:  F1000Res       Date:  2020-06-03

7.  Squamous cell carcinoma of the rectum: Practice trends and patient survival.

Authors:  Sunil W Dutta; Clayton E Alonso; Mark R Waddle; Shiv R Khandelwal; Einsley-Marie Janowski; Daniel M Trifiletti
Journal:  Cancer Med       Date:  2018-11-20       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.